ClinicalTrials.gg
Enrolling by invitationNCT06386679Updated Apr 26, 2024

Amniotic Fluid Mesenchymal Stem Cells Developed for Chondrogenic Treatment (AFCC) Injection in Elderly Knee Osteoarthritis Patients

A Phase 1 interventional study of allogenic amniotic fluid mesenchymal stem cell in Knee Osteoarthritis, sponsored by Siriraj Hospital. Enrolling by invitation at 1 site in Thailand. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-04-26.

Sponsored by Siriraj Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Aug 2023, registered Mar 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
60 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Osteoarthritis, Knee with a site in Thailand — 7 open to participants now, 9 under way, 2 of them phase 3. Osteoarthritis, Knee · Thailand.

Planned enrollment
39th of 40
10 · median 97
Started
2023
with 3 others
Phase 1
Only one
of the 44
Registered
39th of 44
by date

Among the 44 studies in Osteoarthritis, Knee with a site in Thailand, this one is the 39th largest by planned enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2023, is the only one in phase 1, and was the 39th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

7 of the 44 studies in Osteoarthritis, Knee with a site in Thailand are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 60 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Osteoarthritis, Knee with a site in Thailand, or all of them as a file.
02

Study summary

Amniotic fluid mesenchymal stem cells developed for chondrogenic treatment (AFCC) are used to treat elderly patients suffering from knee osteoarthritis (OA). The injection reduces inflammation and promotes the recovery of knee function, leading to an improved quality of life.

Read the detailed description

Ten patients, aged between 60 and 80 of both genders, who were diagnosed with knee osteoarthritis at Kellgren and Lawrence (KL) score 2-3 were selected based on strict inclusion and exclusion criteria. Each patient was treated with a single intra-articular injection of 20 million cells of amniotic fluid mesenchymal stem cells in AFCC type into an OA knee. After the treatment, they were monitored through clinical assessment and laboratory investigation, including blood chemistry test and Magnetic Resonance Imaging (MRI) of the treated knee.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Amniotic fluid mesenchymal stem cells
  • Knee Osteoarthritis
04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 60 to 80 years
  2. The Visual Analog Scale (VAS) score of the subject's knee joint was greater than 4
  3. Knee pain needs at least 15 days of experience.
  4. The Kellgren Lawrence grade of the subject's knee joint was II/III as per the axial position X-ray.
  5. Subjects who understand and voluntarily sign the consent.

Exclusion criteria

Exclusion Criteria:

  1. The subject has secondary osteoarthritis (such as other joint arthritis, major trauma on the study joint in the previous 3 months, axial deviation angle beyond 15 degrees of the bones of the knee joint)
  2. The subject has other known rheumatic or inflammatory diseases (such as rheumatoid arthritis and inflammatory arthritis).
  3. The subject has other conditions that cause knee joint pain (such as cancer, joint tumor)
  4. The subject who awaiting knee surgery
  5. The subject has an underlying disease that affects treatment during 1 year (such as cancer, liver disease, severe kidney disease, SLE)
  6. The subject has a history of vertebral fracture or leg bone fracture
  7. The subject has a nervous system disorder that affects balance (such as stroke or Parkinson's disease)
  8. The subject has an acute or chronic infectious disease
  9. The subject who had evidence of knee surgery
  10. The subject who has received intra-articular or other substances within the last 6 months.
  11. The subject who has received symptomatic slow-acting drugs for osteoarthritis (SYSADOA) within the last 4 months
  12. The subject has a deformity of the knee joint.
  13. The subject has any other pathological conditions
  14. The subject has a communication problem
  15. The subject has claustrophobia
  16. The subject who had surgery to insert a cardiac pacemaker
  17. The subject who had surgery to insert an aneurysm clip
  18. The subject who had surgery to insert a cochlear implant
  19. The subject has any internal metallic objects (such as metal plates, surgical clips, bullets)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    AFCC injection

    Biological: allogenic amniotic fluid mesenchymal stem cell

Interventions

  • Biologicalallogenic amniotic fluid mesenchymal stem cell

    Intra-articular AFCC injection will be given for single knee for each patient in single dose, 20 million of AFCC in each dose

06

What researchers measure

Primary outcomes

  1. Incidence of abnormal physical examination

    The following examinations will be conducted: general appearance, respiratory, abdomen, nervous system, muscoskeletal system and etc. In case of abnormal conditions, they shall be recorded as an adverse event.

    Time frame: Month -3, Day 0, Month 3, 6 and 12

  2. Incidence of abnormal vital sign

    The following assessment will be conducted: heart rate, blood pressure and temperature. In case of abnormal results, they shall be record as an adverse event.

    Time frame: Month -3, Day 0, Month 3, 6 and 12

  3. Incidence of abnormal laboratory test results

    The following lab tests will be conducted: serum chemistry, haematology, liver function test. In case of abnormal results, they shall be recorded as an adverse event.

    Time frame: Day 0, Month 3, 6 and 12

  4. Incidence of abnormal ECG parameters

    The following assessments will be conducted: 12 lead ECG recordings with long Lead II, and two-dimensional echocardiography (2D ECHO; if needed). In case of abnormal conditions, they shall be recorded as an adverse event

    Time frame: Day 0, Month 3, 6 and 12

  5. The type of Adverse event (AE), numbers of AE and proportion of patients with AE.

    AE will be monitored and recorded by the investigator throughout the study.

    Time frame: Day 0 to 7, 14, 30, Month 2 to 12

Secondary outcomes

  1. Pain score

    Change in pain in the affected knee joint in response to treatments using the Visual Analog Score (VAS)

    Time frame: Screening (Month -3), Day 0, Month 3, 6, and 12

  2. Knee Injury and Osteoarthritis Outcome Score (KOOS)

    Assessment changes of knee complaints by using the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire

    Time frame: Screening (Month -3), Day 0, Month 3, 6, and 12

  3. Degree of cartilage change

    Assessment change of joint narrowing space width using Radiography (X-ray) and Magnetic Resonance Imaging (MRI)

    Time frame: Screening (Month -3), Day 0, Month 3, and Month 12

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Nov 2023, 3 months.

Of 61 phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2024
First posted
Apr 26, 2024
StartActual
Aug 17, 2023
Primary completionActual
Nov 23, 2023
CompletionEst.
Mar 2025
Last update
Apr 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06386679
Lead sponsor
Siriraj Hospital
Responsible party
Tatsanee Phermthai, PhD. (Principle Invesitigator, Siriraj Hospital) — Principal investigator
First posted
Apr 26, 2024
Start date
Aug 17, 2023
Primary completion
Nov 23, 2023
Completion
Mar 2025 (estimated)
Last update
Apr 26, 2024

Study contacts

Tatsanee Phermthai, PhD.
study director · Siriraj Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion